According to the law firm Bernstein Liebhard LLP, a ruling issued in the U.S. District Court, Southern District of California on September 10, 2014 has denied plaintiffs a Motion to Compel discovery of defendants’ analysis of a causal association between the drugs and pancreatic cancer (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452). A press release issued by the law firm said that the “plaintiffs’ motion had specifically challenged the sufficiency of defendants’ responses to certain interrogatories. However, U.S. District Judge Anthony Battaglia found that the responses were sufficient given the limited scope of discovery previously set by the Court.”
READ MORE JANUVIA LEGAL NEWS
2013 was not a good year for Januvia. Merck and Co., its manufacturer, reported that the drug’s sales fell 2 percent short of the $4.09 billion it made in 2012, and that its lower US sales were due to safety worries. Meanwhile, big pharma continues to cash in from diabetes. The US Centers for Disease Control and Prevention reports that 29.1 million people in the US alone have either Type 1 or Type 2 diabetes, with about 9 million of that amount undiagnosed.